Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Randomized, Double-Blind, Placebo-controlled, Placebo-Controlled Study to Evaluate the Safety and Activity of Repeated Intranasal Administration of Ampligen® (Poly I:Poly C12U) in Healthy Subjects

Next Previous
X
Search
Trial Profile

A Phase I, Randomized, Double-Blind, Placebo-controlled, Placebo-Controlled Study to Evaluate the Safety and Activity of Repeated Intranasal Administration of Ampligen® (Poly I:Poly C12U) in Healthy Subjects

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rintatolimod (Primary)
  • Indications COVID 2019 infections; Respiratory tract disorders
  • Focus Adverse reactions
  • Acronyms CHDR2049
  • Sponsors AIM ImmunoTech

    • Most Recent Events

    • 02 Dec 2022 According to an AIM ImmunoTech media release, results from this trial will be presented at the British Society for Immunology Congress 2022.
    • 09 Dec 2021 According to an AIM ImmunoTech media release, the company expects to receive the full study report from CHDR in January 2022.
    • 09 Dec 2021 Results published in the AIM ImmunoTech Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top